Abstract: A compound is disclosed, which is useful in treating a mammal having a disease-state characterized by thrombotic activity. The compound is of the following formula: wherein A, B, R1, R2, R3 and R4 are as defined herein or an isomer or isomeric mixture thereof or a pharmaceutically acceptable salt thereof.

Abstract: This invention is directed to acyl piperazine derivatives which are useful as anti-inflammatory agents. This invention is also directed to pharmaceutical compositions containing the compounds of the invention, and methods of using the compounds to treat inflammatory disorders in humans.

Abstract: Methods are provided that are useful in assaying compounds for cognitive enhancing properties, anxiolytic properties, hypnotic properties, or antidepressant properties. These methods involve determining the in vitro efficacy and EC50 of the compounds at defined series of cloned GABAA subtype receptors composed of specific variants of ?, ?, and ? subunits in order to develop and an activity profile for each compound. Optionally, the binding affinities of the compounds at GABAA receptors are also determined. As an additional step the in vivo effects of the compounds may be tested in animal models.

Abstract: Disclosed are compounds of the formula: and the pharmaceutically acceptable salts thereof, wherein W, Q, X, X1, Y and Z are as defined herein. These compounds bind with high selectivity and/or high affinity to the benzodiazepine site of GABAA receptors and are therefore useful in the treatment of central nervous system (CNS) diseases and as probes for the localization of GABAA receptors in tissue samples. Also disclosed are intermediates useful in the preparation of these compounds.

Abstract: A retaining wall block includes a top face, a bottom face, a front face, a back face, and at least one side face. The retaining wall block also includes a recessed surface formed along the bottom face rearward of the front face and forward of the back face. The recessed surface reduces the weight of the block while maintaining the integrity of the front face of the block. The front face and recessed surface may be any geometrical shape including curved or planar. The retaining wall block may also include an aligning element for aligning the blocks when stacked.

Abstract: Apparatus for producing and separating a string of interconnected packing cushions comprises a packing cushion production machine which produces a string of interconnected packing cushions, the string of interconnected packing cushions exiting an output end of the machine at a first velocity, and a separation device associated with the output end of the machine, the separation device adapted to selectively engage the string of interconnected packing cushions and to drive the string at a second velocity, greater than the first velocity, and in doing so to cause the string of interconnected packing cushions to separate.

Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein the A, B, C, D, X, R1, R2, R3, R4, R5, and R6, are variables defined herein, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, depression, overdose with benzodiazepine drugs, and enhancement of memory and alertness.

Abstract: Retaining wall blocks, retaining wall system formed thereby, and method for manufacturing the retaining wall blocks. The blocks are adapted for assembly to form a retaining wall system. A block of an upper row is laterally positioned by positioning it on top of two lower blocks. Each block also includes at least one mounting surface for securing a stabilizing element therewith. The mounting surface can be embodied as a groove which is inset into the upper surface of the blocks. Each block may additionally include opposing front and back body portions, and opposing side body portions, defining a void therein. The blocks may include aligning elements extending upwardly from an upper surface of the block body. The aligning elements of the lower blocks fit into the void of the upper block and assist in aligning the upper block on the lower blocks and, optionally, in securing a reinforcing structure placed between the layers.

Abstract: Compounds of Formula I are provided, as are methods for their preparation. The variables Z1, Z2, Z3, R4, R5, R6, R7, R8 and Ar in the above formula are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).

Abstract: Substituted pyrrolecarboxamide compounds are disclosed. These compounds are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Alzheimer's dementia, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.

Abstract: An apparatus and method that effects selectable width of a roller track conveyance system having multiple roller tracks with asymmetric wall heights. The system includes a clip that connects lower or mating walls of two single roller tracks together. The connected roller tracks each have their own set of rollers, which form respective dispensing surfaces. A removable divider bar, which is capable of being selectively placed into the clips between the connected roller tracks, may be placed to divide the dispensing surfaces into separate surfaces or may be selectively removed to form a larger, single dispensing surface.

Abstract: Methods are provided that are useful in assaying compounds for cognitive enhancing properties, anxiolytic properties, hypnotic properties, or antidepressant properties. These methods involve determining the in vitro efficacy and EC50 of the compounds at defined series of cloned GABAA subtype receptors composed of specific variants of &agr;,&bgr;, and &ggr; subunits in order to develop and an activity profile for each compound. Optionally, the binding affinities of the compounds at GABAA receptors are also determined. As an additional step the in vivo effects of the compounds may be tested in animal models.

Abstract: Disclosed are compounds of the formula: wherein: A, B, C, E, F, and G are substituents as defined herein, which compounds bind to the benzodiazepine site of GABAA receptors and are therefore useful in treatment of central nervous system (CNS) diseases.

Abstract: Disclosed are compounds of the formula: 1

Abstract: Disclosed are compounds of the formula: 1

Abstract: An apparatus and method that effects selectable width of a roller track conveyance system having multiple roller tracks with asymmetric wall heights. The system includes a clip that connects lower or mating walls of two single roller tracks together. The connected roller tracks each have their own set of rollers, which form respective dispensing surfaces. A removable divider bar, which is capable of being selectively placed into the clips between the connected roller tracks, may be placed to divide the dispensing surfaces into separate surfaces or may be selectively removed to form a larger, single dispensing surface.

Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein the A, B, C, D, X, R1, R2, R3, R4, R5, and R6, are variables defined herein, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, depression, overdose with benzodiazepine drugs, and enhancement of memory and alertness.

Abstract: Disclosed are compounds of the formula: 1

Abstract: Disclosed are the compounds of the formula: 1

Abstract: Disclosed are compounds of the formula: 1